Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
313 studies found for:    Open Studies | "Fatty Acids"
Show Display Options
Rank Status Study
21 Unknown  Efficacy of Omega-3/Omega-6 Fatty Acids in Pre-school Children at Risk for ADHD
Condition: Children With ADHD Symptoms >90th Percentile (FBB-ADHS-V); no Beginning or Completion of Psychotherapeutically or Psychopharmalogical Treatment During the Study
Intervention: Dietary Supplement: omega-3/omega-6 fatty acids (PUFAs)
22 Not yet recruiting Effect of Plant Omega-3 and Omega-6 Fatty Acids on Exercise Performance
Condition: Effect of Essential Fatty Acids on Exercise Performance
Interventions: Dietary Supplement: corn syrup;   Dietary Supplement: Polyunsaturated fatty acid
23 Recruiting Nasal Mucin Oral Supplementation Treatment Respiratory Inflammation Using PUFA in Cystic Fibrosis (CF) Patients
Conditions: Cystic Fibrosis;   Dietary Modification
Interventions: Other: polyunsaturated fatty acids n-3;   Other: placebo
24 Unknown  Lipids of the Human Tear Film and Their Effect on Tear Stability
Condition: Blepharitis
Interventions: Drug: doxycycline;   Drug: essential fatty acid;   Drug: azithromycin
25 Unknown  A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)
Conditions: Sickle Cell Disease;   HEMOGLOBIN SS;   Hemoglobin S Beta-0 Thalassemia;   Inflammation;   Quality of Life
Interventions: Dietary Supplement: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA);   Other: Placebo Capsules
26 Recruiting Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity
Condition: Heart Failure
Interventions: Drug: Polyunsaturated fatty acids omega-3;   Drug: Placebo
27 Unknown  Essential Fatty Acids in Adult ADHD
Condition: Adult Attention Deficit Hyperactivity Disorder
Intervention: Dietary Supplement: Essential fatty acids
28 Recruiting Polyunsaturated Fatty Acids in Patients With NAFLD.
Condition: NAFLD
Interventions: Dietary Supplement: Maxicor;   Other: Placebo
29 Recruiting Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
Conditions: Major Depressive Disorder;   Obesity;   Inflammation
Interventions: Other: Placebo;   Drug: EPA 1 g/day;   Drug: EPA 2 g/day;   Drug: EPA 4 g/day
30 Recruiting Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3
Condition: Hyperlipidemia
Interventions: Drug: Omega-3-acid ethyl esters;   Drug: Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
31 Recruiting Omega-3 Fatty Acids as Adjunctive Treatment for Adolescents With Eating Disorders
Condition: Eating Disorder
Intervention: Dietary Supplement: Omega-3 Fatty Acid Supplement
32 Recruiting High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions
Conditions: Mild Concussion;   Brain Concussion;   Cerebral Concussion
Interventions: Dietary Supplement: Docosahexaenoic acid;   Drug: Placebo
33 Unknown  Metabolic Actions of Omega-3 Fatty Acids
Condition: Metabolic Syndrome
Interventions: Dietary Supplement: EPA (marine fatty acids);   Dietary Supplement: Placebo
34 Recruiting The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial
Conditions: Mild Cognitive Impairment;   Subjective Memory Impairment
Interventions: Dietary Supplement: fatty acid/flavonoid blend;   Dietary Supplement: Placebo
35 Unknown  Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention
Condition: Treated Hypertension
Intervention: Drug: Lipoic Acid plus Omega-3 Fatty Acids
36 Recruiting Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction
Conditions: Myocardial Infarction;   Heart Failure;   Myocardial Revascularization;   Atrial Fibrillation
Interventions: Drug: Pikasol;   Other: Corn oil
37 Not yet recruiting Protocol Comparing a Nutraceutical Formulation Consisting of Omega-3 Fatty Acids, Vitamin D, and Vitamins B6 Plus B12 Versus No Treatment in the Prevention or Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients Treated With Docetaxel as Adjuvant Breast Cancer Therapy
Condition: Peripheral Neuropathy in Breast Cancer Patient
Interventions: Dietary Supplement: Vitamin D 2000 IU oral once daily;   Dietary Supplement: Vitamin B6 100 mg oral once daily;   Dietary Supplement: Vitamin B12 100 mcg oral once daily;   Dietary Supplement: Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
38 Unknown  Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
Condition: 22q11 Deletion Syndrome
Interventions: Dietary Supplement: omega-3 PUFAs;   Other: Standard care;   Dietary Supplement: placebo
39 Recruiting Effects of Omega-3 Fatty Acid Supplementation in Acne Patients
Condition: Acne
Interventions: Dietary Supplement: Omega-3;   Dietary Supplement: Placebo
40 Unknown  Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery
Condition: Prostate Cancer
Interventions: Dietary Supplement: omega-3 fatty acids;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: liquid chromatography;   Procedure: biopsy;   Procedure: complementary or alternative medicine procedure

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years